Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02832037 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 509
- Enrollment target
NCT02832037 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 509 participants.
The verdict
NCT02832037, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 509 participants
- Enrollment target
Study Summary
The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
Interventions
- DRUG Placebo
- DRUG BI 425809 dose 1
- DRUG BI 425809 dose 2
- DRUG BI 425809 dose 3
- DRUG BI 425809 dose 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 509 participants |
| Start Date | 2016-07-25 |
| Est. Completion | 2020-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02832037
The ClinicalTrials.gov registry entry for NCT02832037 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02832037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02832037 about?
NCT02832037 is a clinical study titled "Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia". The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.
What is the current status of trial NCT02832037?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 509 participants. The study started on 2016-07-25. Estimated completion is 2020-01-29.
What interventions are being tested in trial NCT02832037?
The interventions under investigation include: Placebo (DRUG), BI 425809 dose 1 (DRUG), BI 425809 dose 2 (DRUG), BI 425809 dose 3 (DRUG), BI 425809 dose 4 (DRUG).
Who is sponsoring clinical trial NCT02832037?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.